Pelthos Therapeutics Inc. (PTHS) - Total Liabilities
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has total liabilities worth $91.52 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Pelthos Therapeutics Inc. to measure how many days the company can operate on defensive assets alone.
Pelthos Therapeutics Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Pelthos Therapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Pelthos Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TW:1762
|
Taiwan | NT$1.28 Billion |
|
MFS High Yield Municipal Closed Fund
NYSE:CMU
|
USA | $61.70 Million |
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
Korea | ₩150.12 Billion |
|
Park Dental Partners, Inc. Common Stock
NASDAQ:PARK
|
USA | $175.23 Million |
|
Jinro Distillers Co. Ltd
KQ:018120
|
Korea | ₩14.06 Billion |
|
Federal Mogul Izmit Piston ve Pim Uretim Tesisleri AS
IS:FMIZP
|
Turkey | TL86.23 Million |
|
Cartier Resources Inc
V:ECR
|
Canada | CA$5.32 Million |
|
MLG OZ Ltd
AU:MLG
|
Australia | AU$174.09 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Pelthos Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Pelthos Therapeutics Inc. assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pelthos Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual total liabilities of Pelthos Therapeutics Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $91.52 Million | +2141.28% |
| 2024-12-31 | $4.08 Million | -37.57% |
| 2023-12-31 | $6.54 Million | +73.89% |
| 2022-12-31 | $3.76 Million | +2.21% |
| 2021-12-31 | $3.68 Million | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more